Hepatitis delta virus messenger RNA (HDV mRNA)

Hepatitis delta virus (HDV) mRNA is an 800-nucleotide, polyadenylated antigenomic RNA transcribed from the circular, single-stranded negative-sense viral genome of HDV. This mRNA serves as the template for the translation of the sole viral protein, hepatitis delta antigen (HDAg), in its two forms: small (S-HDAg) and large (L-HDAg), both essential for HDV replication and assembly. The formation and regulation of HDV mRNA are tightly controlled within the infected cell nucleus using host RNA polymerase II. While research into antiviral strategies has focused on host or viral proteins required for the HDV life cycle (e.g., HDAg prenylation, HBV-mediated virion assembly), there are currently no direct-targeting therapeutics for HDV mRNA itself in clinical use. Key clarification: The entity "Hepatitis D virus mRNA" is a nucleic acid transcript, not a protein or conventional drug target. The true canonical protein target in HDV infection is the hepatitis delta antigen (HDAg), not the mRNA. Thus, this entry is better classified as a viral RNA intermediate and not a standard therapeutic target.

Other names

HDV mRNAHepatitis delta virus mRNAAntigenomic mRNA (in the context of HDV)

Drugs that reduce HDV replication may do so by inhibiting other viral or host proteins (e.g., inhibition of viral entry, viral assembly, or host RNA polymerases involved in HDV RNA synthesis). There are no drugs in clinical use that directly bind or degrade HDV mRNA as their primary mode of action.